Berkshire Hills Bancorp and Brookline to merge in $1.1 bln deal-December 2024-www.financetom.com

Berkshire Hills Bancorp and Brookline to merge in $1.1 bln deal

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Berkshire Hills Bancorp and Brookline to merge in $1.1 bln deal

Dec 16, 2024 6:03 AM

Dec 16 (Reuters) - Regional lenders Berkshire Hills

Bancorp ( BHLB ) and Brookline Bancorp ( BRKL ) have agreed to

merge in an all-stock deal valued at about $1.1 billion, the

companies said on Monday.

Previous page： Berkshire Hills Bancorp and Brookline to merge in $1.1 bln deal Next page： Gatos Silver, First Majestic Get Regulatory Approval for Merger

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Berkshire Hills Bancorp and Brookline to merge in $1.1 bln deal

Dec 16, 2024

Dec 16 (Reuters) - Regional lenders Berkshire Hills Bancorp ( BHLB ) and Brookline Bancorp ( BRKL ) have agreed to merge in an all-stock deal valued at about $1.1 billion, the companies said on Monday. ...

Gatos Silver, First Majestic Get Regulatory Approval for Merger

Dec 16, 2024

08:32 AM EST, 12/16/2024 (MT Newswires) -- Gatos Silver ( GATO ) said Friday that the proposed acquisition of the company by First Majestic (AG) was given unconditional authorization by the Mexican Federal Economic Competition Commission. The transaction is expected to close in January. ...

Mind Medicine Doses First Patient in Phase 3 Study of MM120 to Treat Generalized Anxiety Disorder

Dec 16, 2024

08:35 AM EST, 12/16/2024 (MT Newswires) -- Mind Medicine (MNMD) said Monday that a first patient has been dosed in its phase 3 Voyage study that is evaluating MM120 ODT for the treatment of generalized anxiety disorder. The company said the trial is the first of two phase 3 studies evaluating the efficacy and safety of MM120 ODT versus placebo....

Biohaven Says BHV-1300 Achieves 'Deep Lowering' of Targeted IgG During Early-Stage Trial

Dec 16, 2024

08:32 AM EST, 12/16/2024 (MT Newswires) -- Biohaven ( BHVN ) said Monday that its drug candidate BHV-1300 achieved deep lowering of targeted immunoglobulin G, or IgG, with reduction of more than 60% in the lowest subcutaneous dose tested during the current multiple ascending dose trial. The biopharmaceutical company said that the reduction in IgG occurred within hours of each...